Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 study of V114 versus Prevenar 13 with routine pediatric vaccines in healthy infants
2018-003787-31Phase 3Completed
- Sponsor
- Merck & Co.
- Start
- Jun 2019
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of pneumococcal 15-valent conjugate vaccine in pneumococcal disease (2 arms), sponsored by Merck & Co. Primary endpoint: Percentage of participants that report at least 1 solicited injection-site adverse event. Started Jun 2019; status: completed.
02
Drugs
pneumococcal 15-valent conjugate vaccine
03
Conditions
pneumococcal disease
Beyond the preview
Go deeper on 2018-003787-31.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-003787-31.